According to CNBC, TD Cowen initiated coverage of Faeth Therapeutics at Buy, saying the clinical-stage oncology company is firing on all cylinders. Barclays upgraded Sagimet Biosciences to Overweight from Equal Weight and raised its price target to $18 from $8, while JPMorgan upgraded Lithium Americas to Overweight from Neutral and set a Dec-27 price target of $6, implying 100% upside. Bank of America upgraded Sasol to Buy from Neutral, citing a compelling valuation, and Needham initiated Kodiak AI at Buy with an $8 target, saying it is well positioned for autonomous long-haul trucking.